PL
PLUR.US Pluri Inc.
- Market cap
- USD 15.1M
- P/E
- -
- P/B
- 306.56x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is PLUR.US undervalued?
Graham numberThe Graham number of Pluri Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pluri Inc. fundamental analysis
No fundamental analysis for Pluri Inc. yet.
Pluri Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pluri Inc.
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform. Its product candidates include PLX-PAD, which is composed of maternal mesenchymal stromal cells originating from the …
Full company profilePluri Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pluri Inc. annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 50.0K | 54.0K | 23.0K | 0.00 | 234K | 287K | 326K | 1.34M | 1.02M | 3.04M |
| Gross Profit | -2.18M | 48.0K | 52.0K | -1.55M | -1.37M | -819K | 278K | 322K | 654K | 453K | 1.68M |
| Operating Income | -28.0M | -33.7M | -35.5M | -29.5M | -50.6M | -41.6M | -27.2M | -22.2M | -22.2M | -24.9M | -62.3M |
| EBITDA | -25.6M | -24.1M | -33.3M | -27.4M | -48.4M | -39.4M | -27.7M | -20.2M | -22.1M | -24.4M | -60.1M |
| Net Income | -27.8M | -26.1M | -35.3M | -29.2M | -49.9M | -41.2M | -28.3M | -20.9M | -22.6M | -23.8M | -41.6M |
| EPS | -25 | -20 | -23 | -13 | -14 | -10 | -6.18 | -3.99 | -3.56 | -2.44 | -3.41 |
| Balance Sheet | |||||||||||
| Total Assets | 37.5M | 39.0M | 31.3M | 65.5M | 93.5M | 68.1M | 50.8M | 39.5M | 38.7M | 24.9M | 24.9M |
| Total Liabilities | 7.28M | 10.5M | 9.49M | 9.43M | 36.4M | 35.9M | 35.5M | 34.1M | 39.5M | 42.3M | 41.7M |
| Shareholders' Equity | 30.3M | 28.5M | 21.8M | 56.1M | 57.2M | 30.0M | 13.4M | 96.0K | -6.84M | -23.0M | -22.4M |
| Cash & Short-term Investments | 26.1M | 29.9M | 23.7M | 46.3M | 65.0M | 55.0M | 40.2M | 30.0M | 20.6M | 7.80M | 7.68M |
| Total Debt | - | - | - | 1.59M | 24.6M | 28.8M | 29.9M | 29.6M | 34.1M | 34.9M | 34.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -21.6M | -21.4M | -29.5M | -26.4M | -30.9M | -36.5M | -22.9M | -18.0M | -18.2M | -19.6M | -18.2M |
| Capital Expenditure | 378K | 342K | 239K | 270K | 373K | 280K | 262K | 323K | 1.62M | 633K | 12.0K |
| Free Cash Flow | -22.0M | -21.7M | -29.7M | -26.6M | -31.3M | -36.8M | -23.1M | -18.3M | -19.8M | -20.2M | -18.2M |
| Ratios | |||||||||||
| ROE | -91.9% | -91.6% | -161.8% | -52.0% | -87.3% | -137.3% | -212.1% | -21,758.3% | - | - | - |
| ROA | -74.1% | -67.1% | -112.8% | -44.5% | -53.3% | -60.6% | -55.8% | -52.8% | -58.4% | -95.8% | -166.7% |
| Net Profit Margin | - | -52,252.0% | -65,383.3% | -126,747.8% | - | -17,624.8% | -9,867.9% | -6,407.4% | -1,690.3% | -2,344.6% | -1,368.9% |
| Debt to Equity | - | - | - | 0.03x | 0.43x | 0.96x | 2.24x | 308.46x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pluri Inc. dividends
Pluri Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:8 on Apr 1, 2024.
Who owns Pluri Inc.
- Insiders 49.28%
- Institutions 20.66%
- Public & others 30.06%
- Shares outstanding 14.4M
- Free float 5.75M
Top funds holding PLUR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 2.00K | 0.02% | 0.00% | Aug 2026 |
Top institutions holding PLUR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Renaissance Technologies Corp | 16.1K | 0.12% | -12.38% | Sep 2026 |
| Morgan Stanley - Brokerage Accounts | 2.98K | 0.02% | -3.06% | Jun 2026 |
| EverSource Wealth Advisors, LLC | 2.00K | 0.01% | 0.00% | Jun 2026 |
| UBS Group AG | 1.92K | 0.01% | +1,918.95% | Jun 2026 |
| SIMA Wealth Partners, LLC | 350.00 | 0.00% | 0.00% | Sep 2026 |
| Citigroup Inc | 191.00 | 0.00% | -85.96% | Jun 2026 |
| Wells Fargo & Co | 185.00 | 0.00% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 125.00 | 0.00% | 0.00% | Jun 2026 |
| JPMorgan Chase & Co | 125.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 97.00 | 0.00% | 0.00% | Jun 2026 |
| TD Waterhouse Canada Inc | 95.00 | 0.00% | +2.15% | Jun 2026 |
| Activest Wealth Management | 86.00 | 0.00% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 50.00 | 0.00% | 0.00% | Jun 2026 |
| Winch Advisory Services, LLC | 26.00 | 0.00% | 0.00% | Jun 2026 |
| TFC Financial Management | 19.00 | 0.00% | 0.00% | Jun 2026 |
| IFG Advisory, LLC | 13.00 | 0.00% | 0.00% | Jun 2026 |
| Mercer Global Advisors Inc. | 5.00 | 0.00% | 0.00% | Jun 2026 |
Pluri Inc. company profile
- Company name
- Pluri Inc.
- Ticker
- PLUR.US
- Exchange
- USA Stocks
- Listed since
- Jun 30, 2003
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 92
- Fiscal year end
- June
- Address
- MATAM Advanced Technology Park, Haifa, Israel, 3508409
- Phone
- 972 74 710 8600
- Website
- pluri-biotech.com
About Pluri Inc.
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform. Its product candidates include PLX-PAD, which is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. The company also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. It operates in the field of regenerative medicine, food tech, immunotherapy, as well as contract development and manufacturing organization (CDMO) services for pharmaceutical and biotechnology companies under the PluriCDMO division, and AgTech. It has a collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Pluri Inc. management
8- Mr. Yaacov YanayPresident, CEO & Director · born 1971
- Ms. Liat ZaltsCFO & Treasurer · born 1984
- Mr. Ori ShalemVice President of Operations & Manufacturing
- Mr. Lior RavivChief Technology Officer
- Ms. Hagit GalGeneral Counsel · born 1973
- Ms. Nofar Glaich-DabachVice President of Human Resources
- Ms. Efrat KaduriChief Business Development Officer of Pharma
- Mr. Nimrod Bar ZviChief Commercial Officer